[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-stage-i":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":42},"100548694",false,"NCT06424327","A Registry for People With Lung Cancer","Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology\n\nExclusion Criteria:\n\n* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years\n* History of chemotherapy or radiation therapy for a previous lung cancer\n* Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery\n* Carcinoid tumors\n* History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix\n* Actively receiving treatment for other malignancies\n* Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.\n\n  * Multi-segmental resection from the same lobe is not a criterion for exclusion.","ALL","18 Years",{"count":18,"type":19},600,"ESTIMATED","OBSERVATIONAL","Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.",[23,24],"Lung Cancer","Lung Cancer Stage I",[26,27,28,29,30],"lung cancer","lung cancer stage 1","segmentectomy","Memorial Sloan Kettering Cancer Center","24-127","RECRUITING","2026-05-29",{"date":34,"type":35},"2026-06-01","ACTUAL",{"date":37,"type":35},"2024-05-15",{"date":39,"type":19},"2029-05-15",{"name":29,"class":41},"OTHER",17,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100460869","NCT05281237","Avecure Flexible Microwave Ablation Probe For Lung Nodules","Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule","Inclusion Criteria:\n\n* Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.\n* Pathological proof of target nodule\u002Ftumor type and malignancy with specimen considered adequate per institutional laboratory standards\n* Target nodule\u002Ftumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively\n* Resection\u002Fsurgical candidate (lobectomy or greater)\n* Participants must be at least 22 years old and able to provide consent\n\nExclusion Criteria:\n\n* Subjects in whom flexible bronchoscopy is contraindicated\n* Target nodule \\\u003C 1.0 cm\n* Prior radiation or neo adjuvant chemotherapy of the target nodule\u002Ftumor\n* Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives\n* Pacemaker, implantable cardioverter, or another electronic implantable device\n* Patient cannot tolerate bronchoscopy\n* Patients with coagulopathy\n* Patients in other therapeutic lung cancer studies\n* Subject is pregnant or breastfeeding\n* COVID-19 positive patient at the time of procedure.","22 Years",{"count":51,"type":19},10,"INTERVENTIONAL",[54],"NA","This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.\n\nThis research study involves microwave ablation (MWA)",[57,58,59,24,60,23],"Stage I - II Primary Lung Cancer","Stage I Lung Cancer","Stage II Lung Cancer","Lung Cancer Stage II",[62,58,59,24,60,23],"Stage I - II primary lung cancer","2026-04-07",{"date":65,"type":35},"2026-04-08",{"date":67,"type":35},"2022-06-01",{"date":69,"type":19},"2027-06-30",{"name":71,"class":41},"Beth Israel Deaconess Medical Center",1,{"id":74,"slug":4,"hasResults":10,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":72},"100308072","NCT03290534","Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","Inclusion Criteria:\n\n* Subject signed inform consent\n* Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung\n* Pre-operative criteria\n* Lung nodule suspicious for NSCLC\n* Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen\n* Clinical stage I or Clinical stage II\n* Not pregnant or nursing\n* Negative pregnancy test in premenopausal women\n* Fertile patients must use effective contraception\n* More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer\n\nExclusion Criteria:\n\n\\-",{"count":79,"type":19},40,[81],"PHASE2","This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.",[23,24,60],[85,86,87,88,89,90,26,91],"wedge resection","sublobar resection","brachytherapy","CivaSheet","Pd-103","CivaTech Oncology","lung","2025-04-02",{"date":94,"type":35},"2025-04-04",{"date":96,"type":35},"2019-03-13",{"date":98,"type":19},"2027-12",{"name":90,"class":100},"INDUSTRY",""]